Phenytoin Protects Spinal Cord Axons and Preserves Axonal Conduction and Neurological Function in a Model of Neuroinflammation In Vivo

Journal of Neurophysiology

Volumn 90, Issue 5, 2003, Pages 3566-3571

  Lo, Albert C ^b   Saab, Carl Y ^b   Black, Joel A ^b   Waxman, Stephen G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; NITRIC OXIDE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM ION;

ACTION POTENTIAL; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CUNEATE NUCLEUS; DISEASE ASSOCIATION; INFLAMMATION; MALE; MOUSE; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NERVE FIBER; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PYRAMIDAL TRACT; SODIUM CALCIUM EXCHANGE; SODIUM TRANSPORT; SPINAL CORD; SPINAL CORD ATROPHY;

ANIMALS; AXONAL TRANSPORT; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; NEURAL CONDUCTION; PHENYTOIN; SPINAL CORD;

EID: 0242508548     PISSN: 00223077     EISSN: None     Source Type: Journal    
DOI: 10.1152/jn.00434.2003     Document Type: Article

References (43)

1. 2+ exchanger. J Neurosci 16: 545-552, 1996.
2. Agrawal SK and Fehlings MG. The effect of the sodium channel blocker QX-314 on recovery after acute spinal cord injury. J Neurotrauma 14: 81-88, 1997.
3. Bechtold DA, Kapoor R, and Smith KJ. Axonal protection mediated by flecainide therapy in experimental inflammatory demyelinating disease. J Neurol 249: 204, 2002.
4. Bjartmar C, Kidd G, Mork S, Rudick R, and Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl-aspartate in chronic multiple sclerosis patients. Ann Neurol 48: 893-901, 2000.
5. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA, Hanley D, and Trapp BD. Induction of nitric oxide synthetase in demyelinating regions of multiple sclerosis. Ann Neurol 36: 78-786, 1994.
6. Bolanos JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB, and Heales SJ. Nitric-oxide mediated mitochondrial damage in the brain: mechanism and implications for neurodegenerative diseases. J Neurochem 68: 2227-2240, 1997.
7. Brosamle C and Schwab ME. Cells of origin, course, and temination patterns of the ventral, uncrossed component of the mature rat corticospinal tract. J Comp Neurol 386: 293-303, 1997.
8. Brosamle C and Schwab ME. Ipsilateral, ventral corticospinal tract of the adult rat: ultrastructure, myelination and synaptic connections. J Neurocytol 29: 499-507, 2000.
9. Brosnan CF, Battistini L, Raine C, Dickson DW, and Casadevall A. Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci 16: 152-161, 1994.
10. Brown GC, Bolanos JP, Heales SJ, and Clark JB. Nitric oxide produced by actived astrocytes rapidly and reversibly inhibits cellular respiration. Neurosci Lett 193: 201-204, 1995.
11. + current of mammalian CNS neurons. Neuroreport 6: 1778-1780, 1995.
12. Davie C, Barker G, Webb S, Tofts P, Thompson A, Harding A, McDonald W, and Miller D. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 118: 1583-1592, 1995.
13. Ferguson B, Matyszak MK, Esiri MM, and Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 120: 393-399, 1997.
14. Fern R, Ransom BR, Stys PK, and Waxman SG. Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine, and diazepam. J Pharmacol Exp Ther 266: 1549-1555, 1993.
15. Ganter P, Prince C, and Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 25: 459-467, 1999.
16. Garthwaite G, Goodin DA, Batchelor AM, Leeming K, and Garthwaite J. Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve. Neuroscience 109: 145-155, 2002.
17. 2+-dependent injury of the dorsal columns. J Neurotrauma 14: 299-311, 1997.
18. Imaizumi T, Lankford KL, Waxman SG, Greer CA, and Kocsis JD. Transplanted olfactory ensheathing cells remyelinate and enhance axonal conduction in the demyelinated dorsal columns of the rat spinal cord. J Neurosci 18: 6176-6185, 1998.
19. Kapoor R, Davies M, Blaker PA, Hall SM, and Smith KJ. Blockers of sodium and calcium entry protect axons from nitric-oxide mediated degeneration. Ann Neurol 53: 174-180, 2003.
20. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, and Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157: 267-276, 2000.
21. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 206: 187-191, 2003.
22. Lee MA, Blamire AM, Pendlebury S, Ho KH, Mills KR, Styles P, Palace J, and Matthews PM. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 57: 65-70, 2000.
23. Lo AC, Black JA, and Waxman SG. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport 13: 1909-1912, 2002.
24. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, and Thompson AJ. Spinal cord atrophy and disability in multiple sclerosis. Brain 119: 701-708, 1996.
25. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, and Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123: 308-317, 2000.
26. Mclean MJ and MacDonald RL. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J Pharmacol Exp Ther 227: 779-789, 1983.
27. Narahashi T. Drugs acting on calcium channels. Handbk Exp Phramacol 83: 255-274, 1988.
28. Pinus MR and Abraham NZ Jr. Toxicology and therapeutic drug monitoring (18th ed.). In: Clinical Diaganosis and Management by Laboratory Methods, edited by Henry JB. Phildelphia, PA: Saunders, 1991, p. 349-384.
29. Ragsdale DS and Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res Rev 26: 16-28, 1998.
30. + channels. Proc Natl Acad Sci USA 93: 9270-9275, 1996.
31. Raine CS and Cross AH. Axonal dystrophy as a consequence of long-term demyelination. Lab Invest 60: 714-725, 1989.
32. Rosenberg LJ, Teng YD, and Wrathall JR. Effects of the sodium channel blocker tetrodotoxin on acute white matter pathology after experimental contusive spinal cord injury. J Neurosci 19: 6122-6133, 1999.
33. Segal MM and Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol 77: 3021-3034, 1997.
34. Sloan KE and Stevenson JA. Differential distribution of phosphorylated and non-phosphorylated neurofilaments within the retina and optic nerve of hamsters. Brain Res 437: 365-368, 1987.
35. Smith KJ, Kappor R, and Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9: 69-92, 1999.
36. Stys PK, Ransom BR, and Waxman SG. Tertiary and quaternary local anesthetics protect CNS white matter from anoxic injury at concentrations that do not block excitability. J Neurophysiol 67: 236-240, 1992b.
37. + conductance in rat optic nerve axons. Proc Natl Acad Sci USA 90: 6976-6980, 1993.
38. 2+ exchanger. J Neurosci 12: 430-439, 1992a.
39. Teng YD and Wrathall JR. Local blockade of sodium channels by tetrodotoxin ameliorates tissue loss and long-term functional deficits resulting from experimental spinal cord injury. J Neurosci 17: 4359-4366, 1997.
40. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, and Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285, 1998.
41. White SR, Black PC, Samathanam GK, and Paros KC. Prazosin suppresses development of axonal damage in rats inoculated for experimental allergic encephalomyelitis. J Neuroimmunol 39: 211-218, 1992.
42. Wujek JR, Bjartmar C, Richer E, Ransohoff RM, Yu M, Tuohy VK, and Trapp BD. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 61: 23-32, 2002.
43. Yaari Y, Selzer ME, and Pincus JH. Phenytoin: mechanism of its anticonvulsive action. Ann Neurol 20: 171-184, 1986.